Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data
Authors' conclusion
This study highlights a high burden of glucocorticoid exposure, significant heterogeneity in treatment and high healthcare utilisation in this population.
Study context
- Population
- Patients with incident dermatomyositis (DM) in two large nationally representative US cohorts
- Participants
- 2,475 vs 1,196
- Exposure
- Claims vs electronic health record (EHR)
- Claimsn = 2,475
- EHRn = 1,196
- Outcome
- Characteristics, treatments and outcomes of incident DM
Methodological detailsdescriptive epidemiological study, two inception cohorts: commercial claims and EHR (ENRICH)
- Descriptive epidemiological study
- Two inception cohorts: commercial claims and EHR (ENRICH)
Main finding
As reported in the abstract
| Group | Value | Positive myositis-specific antibody, among 472 with myositis panel results | Mean cumulative GC dose among GC users | All-cause hospitalisation, incidence per 1000 person-years | Malignancy, incidence per 1000 person-years | ILD, incidence per 1000 person-years | Gastrostomy tube placement, incidence per 1000 person-years | Myocarditis, incidence per 1000 person-years |
|---|---|---|---|---|---|---|---|---|
| EHR | 35.0% | 165 (35.0%) | ||||||
| Claims | 1407 mg | 92.2 | 15.3 | 6.4 | 2.9 | 2.1 |
Value
EHR35.0%
Claims— not stated in the abstract
Positive myositis-specific antibody, among 472 with myositis panel results
EHR165 (35.0%)
Claims— not stated in the abstract
Mean cumulative GC dose among GC users
EHR— not stated in the abstract
Claims1407 mg
All-cause hospitalisation, incidence per 1000 person-years
EHR— not stated in the abstract
Claims92.2
Malignancy, incidence per 1000 person-years
EHR— not stated in the abstract
Claims15.3
ILD, incidence per 1000 person-years
EHR— not stated in the abstract
Claims6.4
Gastrostomy tube placement, incidence per 1000 person-years
EHR— not stated in the abstract
Claims2.9
Myocarditis, incidence per 1000 person-years
EHR— not stated in the abstract
Claims2.1
- GC use in the two cohorts, respectively
- 68.7% and 73.8%
Observational data: associations, not effects.
Original publication
Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data. RMD Open. Published 27 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →